Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
Robert K. Leśniak, R. Jeremy Nichols, Thomas J. Montine
Abstract
OPINION article Front. Neurol., 26 October 2022Sec. Experimental Therapeutics Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.1016040
Topics & Concepts
LRRK2Parkinson's diseaseDiseaseMedicineKinaseOncologyBioinformaticsInternal medicineGeneticsBiologyParkinson's Disease Mechanisms and TreatmentsPlant Gene Expression AnalysisNuclear Receptors and Signaling